Pritumumab is under clinical development by Nascent Biotech and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Pritumumab’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 15 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pritumumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Pritumumab is under development for the treatment of brain cancers including glioblastoma (GBM), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), low grade gliomas, brain metastases, meningiomas, chordomas, medulloblastoma, craniopharyngiomas, pituitary tumors orleptomeningeal metastases, pancreatic cancer, lung cancer, breast cancer, colon cancer and Coronavirus disease (COVID-2019). The therapeutic candidate is a human IgG1 kappa antibody. It acts by targeting cells expressing vimentin. It is administered through intravenous route. The therapeutic candidate is developed based on GPEx technology, multiPharm technology and uberkine technology.It was also under development for the treatment of malignant astrocytoma.
Nascent Biotech overview
Nascent Biotech (Nascent) is clinical-stage biopharmaceutical company. The company delivers human monoclonal antibodies and cytokine for the treatment of cancer and a drug discovery platform for identifying new antibodies and antigens for commercialization. It develops Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies such as lung and breast cancer metastases to the brain; and pancreatic cancer. The company offers CLNH5 and MultiPharm, a platform technology proprietary, which have additive and synergistic effects on cancer therapy, diabetes, autoimmunity, and transplantation. Nascent is headquartered in San Diego, California, the US.
Quick View Pritumumab LOA Data
|Highest Development Stage|